Founded in 2015, EdiGene carries the mission to translate the cutting-edge genome editing technologies into novel therapeutics for genetic diseases and cancer, and into creative solutions to advance drug discovery.
In 2018, EdiGene was awarded as one of the ten biotech companies selected by Nature Biotechnology as representing “some of the best (and most richly financed) science that was commercialized from academia”.
In 2019, EdiGene was selected as one of the 50 Most Innovative Companies in China by FAST Company.
Wensheng Wei, Ph.D.
Founder of EdiGene.Principle Investigator at Peking University since 2007, Professor Wei is also Director of Peking University Genome Editing Research Center and Deputy Director of Genome Editing Chapter of the Genetics Society of China. His Group has 30+ publications in top research journals, of which over 20 are in the field of genome editing.
EdiGene has built a strong team of talents with expertise in developing cutting-edge technologies such as genome editing, stem cells and cell therapy, and with experience in innovative drug development and management in multinational and domestic biotechnology companies. Over 40 EdiGene colleagues have advanced degrees with 17 having Ph.D. or M.D. degrees.